Han Tong Medical has successfully raised over 100 million yuan in a Pre-A financing round to expedite the clinical progression and commercialization of its ultrasound renal denervation products, reflecting strong investor confidence in the emerging interventional ultrasound market.

Information on the Target

Han Tong Medical has successfully completed a Pre-A round financing, raising over 100 million yuan. This funding round was led by Da Cheng Caizhi, Jifeng Capital, and Pudong Angel Venture Fund, among others. The raised capital will be utilized to accelerate the clinical advancement and industrialization of Han Tong Medical's ultrasound renal denervation (RDN) products, while also focusing on innovative product research and development in the interventional ultrasound sector. Established in 2022, Han Tong Medical is positioned as a platform-based innovator in the broad vascular field, concentrating on active interventional products, particularly within the vascular interventional ultrasound domain. The firm has developed a fully autonomous ultrasound energy platform and has garnered several accolades, including being recognized as a specialized and innovative small to medium enterprise by the Shanghai government and receiving national-level recognition as a technology-based small and medium enterprise.

This financing round was significantly oversubscribed, reflecting the strong acknowledgment from investors of Han Tong Medical's leading position in the industrialization of interventional ultrasound and their robust confidence in the company’s future development. Dr. Zhao Wanjin, the founder and CEO of Han Tong Medical, expressed gratitude for the trust and support from both new and existing shareholders. He noted that after over two years of rigorous efforts, the company’s proprietary second-generation ultrasound RDN product has advanced quickly to clinical stages, with numerous successful clinical outcomes validating the product's safety and efficacy. Furthermore, the innovation and accumulation of knowledge in the interventional ultrasound sector have earned widespread recognition from both physicians and patients.

Industry Overview in China

The interventional ultrasound industry in China is experiencing significant growth, driven by increasing healthcare demands and advancements in medical technology. As the population ages and chronic diseases become more prevalent, there is a heightened need for minimally invasive treatment options. Interventional ultrasound techn